Index, Almirall in $138M European deal for Kappaproct
By Cormac Sheridan
Tuesday, April 1, 2014
Index Pharmaceuticals AB is getting €5 million (US$6.9 million) up front and could get up to €95 million more in a European licensing deal with Almirall SA for its ulcerative colitis treatment, Kappaproct, which is undergoing a phase III trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.